|Last Price$6.20||Day Change (%)-2.05%|
|Open Price$6.34||Day Change ($)-0.13|
|Day Range6.20–6.38||52-Week Range3.92–14.28|
As of Tue 12/10/2013 05:06 PM EST | USD
Cytokinetics' CYTK ispinesib trial results for head and neck cancer did not yield a statistically significant change in its patients. We are leaving our fair value estimate at $3.50 per share, as we had already assigned a low probability of success for this indication. Our more conservative ...
Research and Markets: Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics - 2013
Cytokinetics faces challenging odds.